BACKGROUND: Missense mutations in the amyloid precursor protein (APP) gene cause early-onset Alzheimer disease (AD). However, little is known regarding the effects of polymorphisms in regulatory sequences of APP on AD susceptibility. OBJECTIVES: To identify polymorphisms in the APP promoter, to test these for associations with AD, and to assess their influence on APP promoter activity in transfected cells. SETTING: Community study of 1013 people of white, African American, or Caribbean Hispanic ethnicity, 65 years and older, residing in northern Manhattan. MAIN OUTCOME MEASURES: The diagnosis of AD was established by stringent criteria, with multiple follow-up examinations over 7 years. RESULTS: We identified 2 polymorphisms in the APP promoter: a rare G-->C variant at -9 and a frequent G-->C variant at +37 relative to the transcription start site. The +37C allele was most frequent in African American patients (18% frequency), followed by Caribbean Hispanic patients (10%) and white patients of European descent (3%). This allele was overrepresented among patients with AD compared with elderly controls (odds ratio [OR], 1.57; 95% confidence interval [CI], 1.08-2.27 in the combined ethnic groups), but this was not significant after adjusting for age, sex, and education (OR, 1.41; 95% CI, 0.93-2.12). A stronger association was found in participants lacking any apolipoprotein-E epsilon4 allele (OR, 2.12; 95% CI, 1.36-3.32 [univariate analysis]; OR, 2.08; 95% CI, 1.26-3.45 after adjusting for age, sex, and education). The -9C allele was not frequent enough to be evaluated for a disease association. Both variants were tested in promoter-reporter assays in U-87 glioma cells, and no differences in promoter activity were detected. CONCLUSIONS: The -9G/C and +37G/C APP promoter polymorphisms are unlikely to contribute strongly to AD susceptibility or to cause major differences in APP expression, but the +37C allele warrants further study for association with AD in larger population samples.
BACKGROUND: Missense mutations in the amyloid precursor protein (APP) gene cause early-onset Alzheimer disease (AD). However, little is known regarding the effects of polymorphisms in regulatory sequences of APP on AD susceptibility. OBJECTIVES: To identify polymorphisms in the APP promoter, to test these for associations with AD, and to assess their influence on APP promoter activity in transfected cells. SETTING: Community study of 1013 people of white, African American, or Caribbean Hispanic ethnicity, 65 years and older, residing in northern Manhattan. MAIN OUTCOME MEASURES: The diagnosis of AD was established by stringent criteria, with multiple follow-up examinations over 7 years. RESULTS: We identified 2 polymorphisms in the APP promoter: a rare G-->C variant at -9 and a frequent G-->C variant at +37 relative to the transcription start site. The +37C allele was most frequent in African American patients (18% frequency), followed by Caribbean Hispanic patients (10%) and whitepatients of European descent (3%). This allele was overrepresented among patients with AD compared with elderly controls (odds ratio [OR], 1.57; 95% confidence interval [CI], 1.08-2.27 in the combined ethnic groups), but this was not significant after adjusting for age, sex, and education (OR, 1.41; 95% CI, 0.93-2.12). A stronger association was found in participants lacking any apolipoprotein-E epsilon4 allele (OR, 2.12; 95% CI, 1.36-3.32 [univariate analysis]; OR, 2.08; 95% CI, 1.26-3.45 after adjusting for age, sex, and education). The -9C allele was not frequent enough to be evaluated for a disease association. Both variants were tested in promoter-reporter assays in U-87 glioma cells, and no differences in promoter activity were detected. CONCLUSIONS: The -9G/C and +37G/C APP promoter polymorphisms are unlikely to contribute strongly to AD susceptibility or to cause major differences in APP expression, but the +37C allele warrants further study for association with AD in larger population samples.
Authors: Ana Miar; Victoria Alvarez; Ana I Corao; Marta Díaz; Belén Alonso; Carmen Martínez; María T Calatayud; Manuel Menéndez; Germán Morís; Eliecer Coto Journal: J Mol Neurosci Date: 2011-03-22 Impact factor: 3.444
Authors: Joshua M Shulman; Kewei Chen; Brendan T Keenan; Lori B Chibnik; Adam Fleisher; Pradeep Thiyyagura; Auttawut Roontiva; Cristin McCabe; Nikolaos A Patsopoulos; Jason J Corneveaux; Lei Yu; Matthew J Huentelman; Denis A Evans; Julie A Schneider; Eric M Reiman; Philip L De Jager; David A Bennett Journal: JAMA Neurol Date: 2013-09-01 Impact factor: 18.302
Authors: Jessie Theuns; Nathalie Brouwers; Sebastiaan Engelborghs; Kristel Sleegers; Veerle Bogaerts; Ellen Corsmit; Tim De Pooter; Cornelia M van Duijn; Peter P De Deyn; Christine Van Broeckhoven Journal: Am J Hum Genet Date: 2006-04-10 Impact factor: 11.025
Authors: Joseph H Lee; Annie J Lee; Lam-Ha Dang; Deborah Pang; Sergey Kisselev; Sharon J Krinsky-McHale; Warren B Zigman; José A Luchsinger; Wayne Silverman; Benjamin Tycko; Lorraine N Clark; Nicole Schupf Journal: Neurobiol Aging Date: 2017-05-03 Impact factor: 4.673
Authors: B V Hooli; G Mohapatra; M Mattheisen; A R Parrado; J T Roehr; Y Shen; J F Gusella; R Moir; A J Saunders; C Lange; R E Tanzi; L Bertram Journal: Neurology Date: 2012-04-04 Impact factor: 9.910
Authors: Jack T Rogers; Ashley I Bush; Hyan-Hee Cho; Deborah H Smith; Andrew M Thomson; Avi L Friedlich; Debomoy K Lahiri; Peter J Leedman; Xudong Huang; Catherine M Cahill Journal: Biochem Soc Trans Date: 2008-12 Impact factor: 5.407
Authors: Shad B Smith; Ellen Mir; Eric Bair; Gary D Slade; Ronald Dubner; Roger B Fillingim; Joel D Greenspan; Richard Ohrbach; Charles Knott; Bruce Weir; William Maixner; Luda Diatchenko Journal: J Pain Date: 2013-12 Impact factor: 5.820
Authors: Ying Jiang; Kerry A Mullaney; Corrinne M Peterhoff; Shaoli Che; Stephen D Schmidt; Anne Boyer-Boiteau; Stephen D Ginsberg; Anne M Cataldo; Paul M Mathews; Ralph A Nixon Journal: Proc Natl Acad Sci U S A Date: 2009-12-28 Impact factor: 11.205